US20010006942A1 - Chemokine receptor peptide vaccines for treatment and prevention of diabetes - Google Patents
Chemokine receptor peptide vaccines for treatment and prevention of diabetes Download PDFInfo
- Publication number
- US20010006942A1 US20010006942A1 US09/754,941 US75494101A US2001006942A1 US 20010006942 A1 US20010006942 A1 US 20010006942A1 US 75494101 A US75494101 A US 75494101A US 2001006942 A1 US2001006942 A1 US 2001006942A1
- Authority
- US
- United States
- Prior art keywords
- chemokine receptor
- peptide
- immunogenic
- peptides
- cxcr3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102000009410 Chemokine receptor Human genes 0.000 title claims abstract description 53
- 108050000299 Chemokine receptor Proteins 0.000 title claims abstract description 53
- 230000002265 prevention Effects 0.000 title abstract description 4
- 229940023041 peptide vaccine Drugs 0.000 title description 3
- 206010012601 diabetes mellitus Diseases 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract description 64
- 230000002163 immunogen Effects 0.000 claims abstract description 42
- 239000000203 mixture Substances 0.000 claims abstract description 28
- 230000028709 inflammatory response Effects 0.000 claims abstract description 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 181
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 116
- 229920001184 polypeptide Polymers 0.000 claims description 47
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 claims description 30
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 claims description 22
- 230000028993 immune response Effects 0.000 claims description 20
- 239000002671 adjuvant Substances 0.000 claims description 17
- 201000006417 multiple sclerosis Diseases 0.000 claims description 16
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 14
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 206010061218 Inflammation Diseases 0.000 claims description 5
- 230000004054 inflammatory process Effects 0.000 claims description 5
- 230000007115 recruitment Effects 0.000 claims description 4
- 229940037003 alum Drugs 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 102000015636 Oligopeptides Human genes 0.000 abstract description 4
- 108010038807 Oligopeptides Proteins 0.000 abstract description 4
- 235000001014 amino acid Nutrition 0.000 description 29
- 210000004027 cell Anatomy 0.000 description 28
- 229940024606 amino acid Drugs 0.000 description 26
- 150000001413 amino acids Chemical group 0.000 description 24
- 108090000623 proteins and genes Proteins 0.000 description 19
- 241000699670 Mus sp. Species 0.000 description 14
- 201000010099 disease Diseases 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 235000018102 proteins Nutrition 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 102000005962 receptors Human genes 0.000 description 13
- 108020003175 receptors Proteins 0.000 description 13
- 239000013598 vector Substances 0.000 description 13
- 230000027455 binding Effects 0.000 description 11
- 238000006467 substitution reaction Methods 0.000 description 11
- 239000000427 antigen Substances 0.000 description 10
- 108091007433 antigens Proteins 0.000 description 10
- 102000036639 antigens Human genes 0.000 description 10
- 201000002491 encephalomyelitis Diseases 0.000 description 10
- 102000019034 Chemokines Human genes 0.000 description 9
- 108010012236 Chemokines Proteins 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 208000023275 Autoimmune disease Diseases 0.000 description 8
- 108060003951 Immunoglobulin Proteins 0.000 description 8
- 102000055771 human CXCR3 Human genes 0.000 description 8
- 102000018358 immunoglobulin Human genes 0.000 description 8
- 239000002953 phosphate buffered saline Substances 0.000 description 8
- 238000007363 ring formation reaction Methods 0.000 description 8
- 102000001189 Cyclic Peptides Human genes 0.000 description 7
- 108010069514 Cyclic Peptides Proteins 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 210000003169 central nervous system Anatomy 0.000 description 7
- 230000003053 immunization Effects 0.000 description 7
- 238000002649 immunization Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 101710098275 C-X-C motif chemokine 10 Proteins 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical group NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
- 239000012636 effector Substances 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 125000005647 linker group Chemical group 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000020477 pH reduction Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 208000016192 Demyelinating disease Diseases 0.000 description 4
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 4
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 4
- 108020004511 Recombinant DNA Proteins 0.000 description 4
- 210000000628 antibody-producing cell Anatomy 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000006472 autoimmune response Effects 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 235000018417 cysteine Nutrition 0.000 description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
- 210000004408 hybridoma Anatomy 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 238000010647 peptide synthesis reaction Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 150000003568 thioethers Chemical class 0.000 description 4
- -1 β-γ-δ-amino acids Chemical class 0.000 description 4
- 206010012305 Demyelination Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- NWMHDZMRVUOQGL-CZEIJOLGSA-N almurtide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)CO[C@@H]([C@H](O)[C@H](O)CO)[C@@H](NC(C)=O)C=O NWMHDZMRVUOQGL-CZEIJOLGSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- LEVWYRKDKASIDU-IMJSIDKUSA-N cystine group Chemical group C([C@@H](C(=O)O)N)SSC[C@@H](C(=O)O)N LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 210000004524 haematopoietic cell Anatomy 0.000 description 3
- 102000046438 human CXCL10 Human genes 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102000001902 CC Chemokines Human genes 0.000 description 2
- 108010040471 CC Chemokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 108091006027 G proteins Proteins 0.000 description 2
- 102000030782 GTP binding Human genes 0.000 description 2
- 108091000058 GTP-Binding Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 150000007649 L alpha amino acids Chemical class 0.000 description 2
- 150000008575 L-amino acids Chemical class 0.000 description 2
- 108700015872 N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 241000700618 Vaccinia virus Species 0.000 description 2
- 206010046865 Vaccinia virus infection Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 239000008365 aqueous carrier Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 206010028417 myasthenia gravis Diseases 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 229940031439 squalene Drugs 0.000 description 2
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 208000007089 vaccinia Diseases 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- BVAUMRCGVHUWOZ-ZETCQYMHSA-N (2s)-2-(cyclohexylazaniumyl)propanoate Chemical compound OC(=O)[C@H](C)NC1CCCCC1 BVAUMRCGVHUWOZ-ZETCQYMHSA-N 0.000 description 1
- BEJKOYIMCGMNRB-GRHHLOCNSA-N (2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-amino-3-phenylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 BEJKOYIMCGMNRB-GRHHLOCNSA-N 0.000 description 1
- YHQZWWDVLJPRIF-JLHRHDQISA-N (4R)-4-[[(2S,3R)-2-[acetyl-[(3R,4R,5S,6R)-3-amino-4-[(1R)-1-carboxyethoxy]-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]amino]-3-hydroxybutanoyl]amino]-5-amino-5-oxopentanoic acid Chemical compound C(C)(=O)N([C@@H]([C@H](O)C)C(=O)N[C@H](CCC(=O)O)C(N)=O)C1[C@H](N)[C@@H](O[C@@H](C(=O)O)C)[C@H](O)[C@H](O1)CO YHQZWWDVLJPRIF-JLHRHDQISA-N 0.000 description 1
- ICLYJLBTOGPLMC-KVVVOXFISA-N (z)-octadec-9-enoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O ICLYJLBTOGPLMC-KVVVOXFISA-N 0.000 description 1
- AOTQGWFNFTVXNQ-UHFFFAOYSA-N 2-(1-adamantyl)acetic acid Chemical compound C1C(C2)CC3CC2CC1(CC(=O)O)C3 AOTQGWFNFTVXNQ-UHFFFAOYSA-N 0.000 description 1
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102100024167 C-C chemokine receptor type 3 Human genes 0.000 description 1
- 101710149862 C-C chemokine receptor type 3 Proteins 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 108050006947 CXC Chemokine Proteins 0.000 description 1
- 102000019388 CXC chemokine Human genes 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108010039939 Cell Wall Skeleton Proteins 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 208000000666 Fowlpox Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 101150106931 IFNG gene Proteins 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- DBTDEFJAFBUGPP-UHFFFAOYSA-N Methanethial Chemical compound S=C DBTDEFJAFBUGPP-UHFFFAOYSA-N 0.000 description 1
- 108700020354 N-acetylmuramyl-threonyl-isoglutamine Proteins 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 241000237988 Patellidae Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108010010974 Proteolipids Proteins 0.000 description 1
- 102000016202 Proteolipids Human genes 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 238000011803 SJL/J (JAX™ mice strain) Methods 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108010034949 Thyroglobulin Proteins 0.000 description 1
- 102000009843 Thyroglobulin Human genes 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108010015780 Viral Core Proteins Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000006470 autoimmune attack Effects 0.000 description 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229960002713 calcium chloride Drugs 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000006355 carbonyl methylene group Chemical group [H]C([H])([*:2])C([*:1])=O 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 210000004520 cell wall skeleton Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000004940 costimulation Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- HJZLEGIHUQOJBA-UHFFFAOYSA-N cyclohexane propionic acid Chemical compound OC(=O)CCC1CCCCC1 HJZLEGIHUQOJBA-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000006539 extracellular acidification Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229920000140 heteropolymer Polymers 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 210000004754 hybrid cell Anatomy 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 239000000568 immunological adjuvant Substances 0.000 description 1
- 230000002134 immunopathologic effect Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- SRJOCJYGOFTFLH-UHFFFAOYSA-N isonipecotic acid Chemical compound OC(=O)C1CCNCC1 SRJOCJYGOFTFLH-UHFFFAOYSA-N 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- JMUHBNWAORSSBD-WKYWBUFDSA-N mifamurtide Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)OCCNC(=O)[C@H](C)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O JMUHBNWAORSSBD-WKYWBUFDSA-N 0.000 description 1
- 229960005225 mifamurtide Drugs 0.000 description 1
- 108700007621 mifamurtide Proteins 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 1
- NKAAEMMYHLFEFN-UHFFFAOYSA-M monosodium tartrate Chemical compound [Na+].OC(=O)C(O)C(O)C([O-])=O NKAAEMMYHLFEFN-UHFFFAOYSA-M 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 108010064578 myelin proteolipid protein (139-151) Proteins 0.000 description 1
- 210000003007 myelin sheath Anatomy 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229960002816 potassium chloride Drugs 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 229940124551 recombinant vaccine Drugs 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229960004249 sodium acetate Drugs 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229960002668 sodium chloride Drugs 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940014800 succinic anhydride Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 229960002175 thyroglobulin Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- XETCRXVKJHBPMK-MJSODCSWSA-N trehalose 6,6'-dimycolate Chemical compound C([C@@H]1[C@H]([C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](COC(=O)C(CCCCCCCCCCC3C(C3)CCCCCCCCCCCCCCCCCC)C(O)CCCCCCCCCCCCCCCCCCCCCCCCC)O2)O)O1)O)OC(=O)C(C(O)CCCCCCCCCCCCCCCCCCCCCCCCC)CCCCCCCCCCC1CC1CCCCCCCCCCCCCCCCCC XETCRXVKJHBPMK-MJSODCSWSA-N 0.000 description 1
- 229940117013 triethanolamine oleate Drugs 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Definitions
- the present invention relates to novel compositions and methods for inhibiting inflammatory responses associated with autoimmune diseases.
- it relates to vaccination with peptides from the extracellular regions of chemokine receptor molecules.
- Chemokines constitute a family of small molecular weight cytokines that are produced in inflammation and regulate leukocyte recruitment. These molecules are ligands for seven transmembrane G protein linked receptors that induce a signaling cascade costimulation for T cell activation in addition to participating in transendothelial migration of leukocytes (Oppenheim et al. Ann. Rev. Immunol. 9:617-648 (1991), Premback et al. Nat. Med. 2:1174-1178 (1996)). Two subfamilies of chemokines, referred to as CC and CXC, have been discovered.
- CC and CXC chemokines are distinct from each other in their N terminal amino acid sequence which starts either with cysteine-cysteine or cysteine-X-cysteine where X is typically another L-amino acid. They are also distinct in their binding pattern to their receptors. For example, the CC chemokines bind to CC receptors and not to CXC receptors and vice versa.
- IP-10 has been demonstrated to be specific for this lineage of hemopoietic cells (Taub et al. J. Exp. Med. 177:1809-1814 (1993)); Carr, et al. Proc. Natl. Acad. Sci. USA 91:3652-3656 (1994); and Farber, J. Leukoc. Biol. 61:246-257 (1997).
- MBP-immunized rats intrathecaly infused with an antisense phosphorothioate oligonucleotide to crg-2 show reduced disease clinical score of EAE (Wojcik, et al. J. Pharmacol. Exp. Ther. 278:404-410 (1996)).
- higher expression of some of the chemokine receptors such as CXCR3 on IL2 activated human T lymphocytes and not on resting T lymphocytes has been demonstrated (Loetscher et al. J Exp. Med. 184:963-969 (1996)).
- MS Multiple sclerosis
- CNS central nervous system
- the present invention provides methods of inducing an immune response against a chemokine receptor molecule in a patient.
- the methods comprise administering to the patient an immunologically effective amount of a pharmaceutical composition comprising an adjuvant and an immunogenic chemokine receptor polypeptide from a extracellular region of a chemokine receptor molecule, for example CXCR3.
- the immunogenic peptides are preferably conformationally constrained, for example by cyclization.
- the length of the immunogenic peptide is not critical to the invention.
- the peptide consists of between about 10 and about 50 residues, more often between about 15 and about 30 residues.
- Exemplary immunogenic peptides of the invention include MVLEVSDHQVLNDAEVAALL, ENFSSSYDYGENESDSCCTS, PPCPQDFSLNFDRAFLPA, DAAVQWVFGSGLCKV, SAHHDERLNATHCQYN, FPQVGRTALRVLQLVAG, and DILMDLGALARNCGRESRVDVAKS.
- the immunogenic peptides can be administered by any of a number of means. Typically they are administered parenterally.
- the adjuvant can be, for example, alum.
- the method are used to inhibit recruitment of T cells to inflammation sites in a patient.
- the inflammatory response is associated with an autoimmune disease, such as multiple sclerosis.
- the invention also provides pharmaceutical compositions suitable for use in the above methods.
- peptide is used interchangeably with “oligopeptide” or “polypeptide” in the present specification to designate a series of residues, typically L-amino acids, connected one to the other typically by peptide bonds between the ⁇ -amino and carbonyl groups of adjacent amino acids.
- cyclic peptide refers to peptides in which the N-terminal residue is linked to the C-terminal residue either directly or through an intermediate. Examples of links between the two residues include disulfide bonds and thioether linkages as described below.
- an “immunogenic chemokine receptor polypeptide” of the present invention is a polypeptide capable of eliciting an immune response against a chemokine receptor molecule associated with inflammation in autoimmune responses in a patient, such as multiple sclerosis.
- the sequence of residues in the polypeptide will be identical to or substantially identical to a polypeptide sequence in a chemokine receptor molecule.
- a polypeptide of the invention that has a sequence “from a extracellular region of a chemokine receptor molecule” is polypeptide that has a sequence either identical to or substantially identical to the naturally occurring chemokine receptor amino acid sequence of the region.
- extracellular region of a chemokine receptor molecule is a region of the molecule which is exposed on the surface of a cell expressing the native molecule.
- FIG. 1 provides a schematic of the extracellular domains of the human CXCR3 molecule. This molecule has four extracellular regions designated as SP-1, SP-2, SP-3 and SP-4, starting from the N-terminus.
- adjuvant refers to any substance which, when administered with or before an antigen, increases and/or qualitatively affects the immune response against the antigen in terms of antibody formation and/or the cell-mediated response. Exemplary adjuvants for use in the present invention are provided below.
- the phrases “isolated” or “biologically pure” refer to material which is substantially or essentially free from components which normally accompany it as found in its native state.
- the chemokine receptor polypeptides of this invention do not contain materials normally associated with their in situ environment, e.g., other surface proteins on T cells. Even where a protein has been isolated to a homogenous or dominant band, there are trace contaminants in the range of 5-10% of native protein which co-purify with the desired protein. Isolated polypeptides of this invention do not contain such endogenous co-purified protein.
- residue refers to an amino acid or amino acid mimetic incorporated in a oligopeptide by an amide bond or amide bond mimetic.
- FIG. 1 shows acidification rate changes due to the binding of anti-human CXCR3 Mab or P-10 to CXCR3-NSO transfectants.
- 5X10 5 CXCR3-NSO transfectant cells and untransfected “BONZO-NSO” cells (negative control) were spotted in the microphysiometer chambers along with agarose and 1, 5, 10 mglml anti-CXCR3 (FIG 1 a ) or IP-10 (FIG 1 b ) was pumped for 10 min.
- Untransfected BONZO-NSO cells did not show any change in acidification rate changes either with the anti-CXCR3 antibody, or IP-10.
- the arrow indicates the time that ligands were added to the cells.
- FIG. 2 shows the structure of the seven transmembrane G-protein coupled human CXCR3. Only amino acids in the extracellular domains are given
- FIG. 3 is a schematic of the experiments in which peptides vaccines of the invention were used to prevent EAE in mice.
- FIG. 3 shows the results of experiments in which peptides vaccines of the invention were used to prevent EAE in mice.
- the present invention provides immunogenic polypeptides derived from chemokine receptor protein sequences for use in compositions and methods for the treatment and prevention of inflammatory responses.
- the polypeptides are capable of inducing an immune response against chemokine receptor molecules which mediate inflammatory responses associated with various diseases.
- the polypeptides of the invention are conformationally constrained (e.g., cyclized) and derived from extracellular regions of human CXCR3. Immunization with the polypeptides of the invention provides a specific immune response to particular chemokine receptors and results in the specific inhibition of the inflammatory responses mediated by these molecules.
- the methods can be used to treat any inflammatory response mediated by chemokines.
- the methods are useful for treatment of autoimmune diseases, such as multiple sclerosis.
- Multiple sclerosis a human demyelinating disease which afflicts 600,000 individuals worldwide, results from damage of the myelin sheath of oligodendroglial cells in the Central Nervous System (CNS).
- CNS Central Nervous System
- the central mediator of autoimmune attack is believed to be host CD4+T cells specific for one or more autoantigens in the CNS, with subsequent production of an array of tissue-destructive inflammatory mediators following autoantigen-activation of these cells.
- immunohistochemical analysis of the focal plaques of demyelination which occur in the brains of MS patients as a consequence of MS pathology have revealed the presence of CD4+T cells infiltrating these plaques.
- EAE experimental allergic encephalomyelitis
- CD4+MHC class II restricted T cells CD4+MHC class II restricted T cells.
- SJL/J mice the disease can display a relapsing-remitting clinical course of paralysis, which makes it an ideal system to study the efficacy of various immunoregulatory strategies both in the prevention and treatment of disease.
- the current invention is focused not on the cytokine-producing phenotype of autoreactive T cells in this disease setting, but on their trafficking from the host circulation to the site of pathology, for example within the CNS in the case of MS.
- hemopoietic cell migration is regulated by chemokines.
- the invention provides peptide vaccines against the 7-transmembrane chemokine receptor designated CXCR3. Consistent with the chemotactic fingerprint of IP-10, CXCR3 is expressed exclusively on activated effector T lymphocytes.
- Exemplary peptides of the invention include peptides derived from the extracellular domains of the CXCR3 protein are presented in Table 1.
- the peptides of the invention are cyclized. Methods for cyclizing peptides are described in detail below. In those cases in which the peptides are cyclized by disulfide linkages, one of skill will recognize that the peptides will further comprise cysteine residues either within the peptide or at each terminus.
- Polypeptides suitable for use in the present invention can be obtained in a variety of ways. Conveniently, they can be synthesized by conventional techniques employing automatic synthesizers, such as the Beckman, Applied Biosystems, or other commonly available peptide synthesizers using well known protocols. They can also be synthesized manually using techniques well known in the art. See, e.g. Stewart and Young, Solid Phase Peptide Synthesis, (Rockford, Ill., Pierce), 2d Ed. (1984).
- DNA sequences which encode the particular chemokine receptor polypeptide may be cloned and expressed to provide the peptide.
- Nucleic acid molecules encoding chemokine receptors are known in the art and sequences of such genes are available, for instance, from GenBank (see, e.g., GenBank Accession Nos. HSU83326 HSU97123, and AF005058).
- Standard techniques can be used to screen cDNA libraries to identify sequences encoding the desired sequences (see, Sambrook et al., Molecular Cloning—A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1989). Fusion proteins (those consisting of all or part of the amino acid sequences of two or more proteins) can be recombinantly produced. In addition, using in vitro mutagenesis techniques, unrelated proteins can be mutated to comprise the appropriate sequences.
- Chemokine receptor proteins from a variety of natural sources are also conveniently isolated using standard protein purification techniques.
- Peptides can be purified by any of a variety of known techniques, including, for example, reverse phase high-performance liquid chromatography (HPLC), ion-exchange or immunoaffinity chromatography, separation by size, or electrophoresis (See, generally, Scopes, R., Protein Purification, Springer-Verlag, N.Y. (1982)).
- the immunogenic chemokine receptor polypeptides of the present invention may be modified to provide a variety of desired attributes, e.g., improved pharmacological characteristics, while increasing or at least retaining substantially all of the biological activity of the unmodified peptide.
- the peptides can be modified by extending, decreasing the amino acid sequence of the peptide. Substitutions with different amino acids or amino acid mimetics can also be made.
- the peptides employed in the subject invention need not be identical to peptides disclosed in the Example section, below, so long as the subject peptides are able to induce an immune response against the desired chemokine receptor molecule. Thus, one of skill will recognize that a number of conservative substitutions (described in more detail below) can be made without substantially affecting the activity of the peptide.
- Single amino acid substitutions, deletions, or insertions can be used to determine which residues are relatively insensitive to modification. Substitutions are preferably made with small, relatively neutral moieties such as Ala, Gly, Pro, or similar residues. The effect of single amino acid substitutions may also be probed using D-amino acids. The number and types of residues which are substituted or added depend on the spacing necessary between essential contact points and certain functional attributes which are sought (e.g., hydrophobicity versus hydrophilicity). Increased immunogenicity may also be achieved by such substitutions, compared to the parent peptide. In any event, such substitutions should employ amino acid residues or other molecular fragments chosen to avoid, for example, steric and charge interference which might disrupt binding.
- the substituting amino acids need not be limited to those naturally occurring in proteins, such as L- ⁇ -amino acids, or their D-isomers.
- the peptides may be substituted with a variety of moieties such as amino acid mimetics well known to those of skill in the art.
- a peptide bond mimetic of the invention includes peptide backbone modifications well known to those skilled in the art. Such modifications include modifications of the amide nitrogen, the ⁇ -carbon, amide carbonyl, complete replacement of the amide bond, extensions, deletions or backbone crosslinks. See, generally, Spatola, Chemistry and Biochemistry of Amino Acids, Peptides and Proteins, Vol. VII (Weinstein ed., 1983).
- Amino acid mimetics may also be incorporated in the peptides.
- An “amino acid mimetic” as used here is a moiety other than a naturally occurring amino acid that conformationally and functionally serves as a substitute for an amino acid in a polypeptide of the present invention. Such a moiety serves as a substitute for an amino acid residue if it does not interfere with the ability of the peptide to illicit an immune response against the appropriate chemokine receptor molecule.
- Amino acid mimetics may include non-protein amino acids, such as ⁇ - ⁇ - ⁇ -amino acids, ⁇ - ⁇ - ⁇ -imino acids (such as piperidine-4-carboxylic acid) as well as many derivatives of L- ⁇ -amino acids.
- amino acid mimetics include cyclohexylalanine, 3-cyclohexylpropionic acid, L-adamantyl alanine, adamantylacetic acid and the like.
- Peptide mimetics suitable for peptides of the present invention are discussed by Morgan and Gainor, (1989) Ann. Repts. Med. Chem. 24:243-252/.
- the peptides employed in the subject invention need not be identical, but may be substantially identical, to the corresponding sequence of the target chemokine receptor molecule. Therefore, the peptides may be subject to various changes, such as insertions, deletions, and substitutions, either conservative or non-conservative, where such changes might provide for certain advantages in their use.
- the polypeptides of the invention can be modified in a number of ways so long as they comprise a sequence substantially identical (as defined below) to a sequence in the target region of the chemokine receptor molecule.
- sequence identity means that two polynucleotide sequences are identical (i.e., on a nucleotide-by-nucleotide basis) over a window of comparison.
- percentage of sequence identity is calculated by comparing two optimally aligned sequences over the window of comparison, determining the number of positions at which the identical residues occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison (i.e., the window size), and multiplying the result by 100 to yield the percentage of sequence identity.
- the term “substantial identity” means that two peptide sequences, when optimally aligned, such as by the programs GAP or BESTFIT using default gap weights, share at least 80 percent sequence identity, preferably at least 90 percent sequence identity, more preferably at least 95 percent sequence identity or more (e.g., 99 percent sequence identity).
- residue positions which are not identical differ by conservative amino acid substitutions.
- Conservative amino acid substitutions refer to the interchangeability of residues having similar side chains.
- a group of amino acids having aliphatic side chains is glycine, alanine, valine, leucine, and isoleucine; a group of amino acids having aliphatic-hydroxyl side chains is serine and threonine; a group of amino acids having amide-containing side chains is asparagine and glutamine; a group of amino acids having aromatic side chains is phenylalanine, tyrosine, and tryptophan; a group of amino acids having basic side chains is lysine, arginine, and histidine; and a group of amino acids having sulfur-containing side chains is cysteine and methionine.
- Preferred conservative amino acids substitution groups are: valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, and asparagine-glutamine.
- the polypeptides of the invention typically comprise at least about 10 residues and more preferably at least about 15 residues from the extracellular domain of a chemokine receptor. In certain embodiments the peptides will not exceed about 50 residues and typically will not exceed about 30 residues. For instance, the peptides described below consist of about 15 to about 25 residues.
- the immunogenic peptides are conformationally constrained. Means for achieving this are well known in the art (see, e.g., Hruby and Bonner in Methods in Molecular Biology, Volume 35: Peptide Synthesis Protocols Pennington and Dunn eds (Humana Press, Totowa, N.J., 1994).
- a preferred means for preparing conformationally constrained peptides is through cyclization. Any method commonly used to produce cyclized oligopeptides can be used to produce the peptides of the invention. For example, in certain embodiments the peptides will include cysteine residues at both termini, which allow the production of cyclic peptides through disulfide linkages.
- cyclic peptide Treatment of a such a peptide with an oxidizing agent such as oxygen, iodine or similar agent will produce a cyclic peptide which may be further purified using chromatographic or other methods of chemical purification.
- Construction of cyclic peptides can also be accomplished through thioether linkages. For instance, N-bromoacetyl-derivatized peptides can be reacted with sulfhydryl-containing residues, such as cysteine. Cyclization occurs by reaction of the free sulfhydryl of cysteine in the peptide with the bromoacetyl group to form a thioether linkage (Robey et al., Anal. Biochem. 177:373-7 (1989) and U.S. Pat. No. 5,066,716).
- linkers can be used to join the amino and carboxyl termini of a peptide.
- the linker is capable of forming covalent bonds to both the amino and carboxyl terminus.
- Suitable linkers are well known to those of skill in the art and include, but are not limited to, straight or branched-chain carbon linkers, heterocyclic carbon linkers, or peptide linkers.
- the linkers may be joined to the carboxyl and amino terminal amino acids through their side groups (e.g., through a disulfide linkage to cysteine) or through the alpha carbon amino and carboxyl groups of the terminal amino acids.
- cyclizations may include formation of carba analogs and thioethers (Lebl et al. in Peptides 1986 Proceedings of the 19th European Peptide Symposium pp. 341-344; Robey et al., Anal Biochem. 177:373-7 (1989) and U.S. Pat. No. 5,066,716), bis-thioethers (Mosberg et al.
- Bridging is a special type of cyclization in which distant sites in a peptide are brought together using separate bridging molecules or fragments.
- Bridging molecules may include, for example, succinic anhydride molecules (Charpentier, B., et al., supra), and carboxymethylene fragments (Thaisrivongs, S., et al., supra). Bridging by metals can also be used (Ozeki, E., et al., supra).
- the peptides include two or more cystine residues.
- the cystines can be substituted or added within the peptide or at either terminus.
- the position of the cystines is not critical so long as disulfide linkages can form between them which allow the production of cyclic peptides.
- treatment of such a peptide with an oxidizing agent such as oxygen, iodine or similar agent will produce a cyclic peptide which may be further purified using chromatographic or other methods of chemical purification.
- antibodies raised against peptides of the invention can be used to inhibit inflammatory responses.
- Antibodies can be raised to the peptides of the present invention using techniques well known to those of skill in the art.
- Anti-idiotypic antibodies can also be generated. The following discussion is presented as a general overview of the techniques available; however, one of skill will recognize that many variations upon the following methods are known.
- a number of immunogens can be used to produce antibodies specifically reactive with the peptides.
- the entire chemokine receptor molecule or fragments containing the desired sequence can be used.
- Synthetic peptides as disclosed here can be used either in linear form or cyclized.
- an immunogen preferably a purified polypeptide, a polypeptide coupled to an appropriate carrier (e.g., GST, keyhole limpet hemanocyanin, etc.), or a polypeptide incorporated into an immunization vector such as a recombinant vaccimia virus (see, U.S. Pat. No. 4,722,848) is mixed with an adjuvant and animals are immunized with the mixture.
- an immunogen preferably a purified polypeptide, a polypeptide coupled to an appropriate carrier (e.g., GST, keyhole limpet hemanocyanin, etc.), or a polypeptide incorporated into an immunization vector such as a recombinant vaccimia virus (see, U.S. Pat. No. 4,722,848) is mixed with an adjuvant and animals are immunized with the mixture.
- the animal's immune response to the immunogen preparation is monitored by taking test bleeds and determining the titer of re
- monoclonal antibodies from various mammalian hosts, such as mice, rodents, primates, humans, etc.
- Description of techniques for preparing such monoclonal antibodies are found in, e.g., Stites et al. (eds.) Basic and Clinical Immunology (4th ed.) Lange Medical Publications, Los Altos, Calif., and references cited therein; Harlow and Lane, Supra; Goding (1986) Monoclonal Antibodies: Principles and Practice (2d ed.) Academic Press, New York, N.Y.; and Kohler and Milstein (1975) Nature 256:495-497. Summarized briefly, this method proceeds by injecting an animal with an immunogen.
- hybridomas The animal is then sacrificed and cells taken from its spleen, which are fused with myeloma cells. The result is a hybrid cell or “hybridoma” that is capable of reproducing in vitro.
- the population of hybridomas is then screened to isolate individual clones, each of which secrete a single antibody species to the immunogen. In this manner, the individual antibody species obtained are the products of immortalized and cloned single B cells from the immune animal generated in response to a specific site recognized on the immunogenic substance.
- Alternative methods of immortalization include transformation with Epstein Barr Virus, oncogenes, or retroviruses, or other methods known in the art. Colonies arising from single immortalized cells are screened for production of antibodies of the desired specificity and affinity for the antigen, and yield of the monoclonal antibodies produced by such cells is enhanced by various techniques, including injection into the peritoneal cavity of a vertebrate (preferably mammalian) host. Specific monoclonal and polyclonal antibodies will usually bind with a K D of at least about 0.1 mM, more usually at least about 50 ⁇ M, and most preferably at least about 1 ⁇ M or better.
- the peptides and antibodies of the invention will be labeled by joining, either covalently or non-covalently, a substance which provides for a detectable signal.
- labels and conjugation techniques are known and are reported extensively in both the scientific and patent literature. Suitable labels include radionucleotides, enzymes, substrates, cofactors, inhibitors, fluorescent moieties, chemiluminescent moieties, magnetic particles, and the like. Patents teaching the use of such labels include U.S. Pat. Nos. 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149; and 4,366,241.
- recombinant immunoglobulins may be produced. See, Cabilly, U.S. Pat. No. 4,816,567; and Queen et al. (1989) Proc. Nat'l Acad. Sci. USA 86: 10029-10033.
- the antibodies of this invention can also be administered to an organism (e.g., a human patient) for therapeutic purposes (e.g., to inhibit an autoimmune response).
- Antibodies administered to an organism other than the species in which they are raised are often immunogenic.
- murine antibodies administered to a human often induce an immunologic response against the antibody (e.g., the human anti-mouse antibody (HAMA) response) on multiple administrations.
- the immunogenic properties of the antibody are reduced by altering portions, or all, of the antibody into characteristically human sequences thereby producing chimeric or human antibodies, respectively.
- Chimeric antibodies are immunoglobulin molecules comprising a human and non-human portion. More specifically, the antigen combining region (or variable region) of a humanized chimeric antibody is derived from a non-human source (e.g., murine) and the constant region of the chimeric antibody (which confers biological effector function to the immunoglobulin) is derived from a human source. The chimeric antibody should have the antigen binding specificity of the non-human antibody molecule and the effector function conferred by the human antibody molecule.
- a large number of methods of generating chimeric antibodies are well known to those of skill in the art (see, e.g., U.S. Pat.
- recombinant DNA vector is used to transfect a cell line that produces an antibody against a peptide of the invention.
- the novel recombinant DNA vector contains a “replacement gene” to replace all or a portion of the gene encoding the immunoglobulin constant region in the cell line (e.g., a replacement gene may encode all or a portion of a constant region of a human immunoglobulin, or a specific immunoglobulin class), and a “target sequence” which allows for targeted homologous recombination with immunoglobulin sequences within the antibody producing cell.
- a recombinant DNA vector is used to transfect a cell line that produces an antibody having a desired effector function, (e.g., a constant region of a human immunoglobulin) in which case, the replacement gene contained in the recombinant vector may encode all or a portion of a region of an antibody and the target sequence contained in the recombinant vector allows for homologous recombination and targeted gene modification within the antibody producing cell.
- a desired effector function e.g., a constant region of a human immunoglobulin
- the resulting chimeric antibody may define the same antigen and/or have the same effector function yet be altered or improved so that the chimeric antibody may demonstrate a greater antigen specificity, greater affinity binding constant, increased effector function, or increased secretion and production by the transfected antibody producing cell line, etc.
- this invention provides for fully human antibodies.
- Human antibodies consist entirely of characteristically human polypeptide sequences.
- the human antibodies of this invention can be produced in using a wide variety of methods (see, e.g., Larrick et al., U.S. Pat. No. 5,001,065).
- the human antibodies of the present invention are produced initially in trioma cells. Genes encoding the antibodies are then cloned and expressed in other cells, particularly, nonhuman mammalian cells.
- the general approach for producing human antibodies by trioma technology has been described by Ostberg et al. (1983), Hybridoma 2:361-367, Ostberg, U.S. Pat. No.
- triomas The antibody-producing cell lines obtained by this method are called triomas because they are descended from three cells; two human and one mouse. Triomas have been found to produce antibody more stably than ordinary hybridomas made from human cells.
- the peptides or antibodies (typically monoclonal antibodies) of the present invention and pharmaceutical compositions thereof are useful for administration to mammals, particularly humans, to treat and/or prevent deleterious immune inflammatory responses, particularly those associated with autoimmune responses.
- autoimmune diseases include myasthenia gravis (MG), multiple sclerosis (MS), systemic lupus erythematosis (SLE), rheumatoid arthritis (RA), insulin-dependent diabetes mellitus (IDDM), and the like.
- Suitable formulations are found in Remington's Pharmaceutical Sciences, Mack Publishing Company, Philadelphia, PA, 17th ed. (1985).
- the immunogenic peptides or antibodies of the invention are administered prophylactically or to an individual already suffering from the disease.
- the peptide compositions are administered to a patient in an amount sufficient to elicit an effective immune response to the chemokine receptor molecule from which the peptides are derived.
- An effective immune response is one that inhibits recruitment of T cells to sites of inflammation.
- Boosting dosages are typically from about 0.1 mg to about 0.5 mg of peptide using a boosting regimen over weeks to months depending upon the patient's response and condition.
- a suitable protocol would include injection at time 0, 4, 2, 6, 10 and 14 weeks, followed by further booster injections at 24 and 28 weeks.
- the peptides and compositions of the present invention may generally be employed in serious disease states, that is, life-threatening or potentially life threatening situations. In such cases, in view of the minimization of extraneous substances and the relative nontoxic nature of the peptides, it is possible and may be felt desirable by the treating physician to administer substantial excesses of these peptide compositions.
- Vaccine compositions containing the peptides are administered prophylactically to a patient susceptible to or otherwise at risk of the disease to elicit an immune response against the target Chemokine receptor antigen.
- compositions are intended for parenteral or oral administration.
- the pharmaceutical compositions are administered parenterally, e.g., subcutaneously, intradernally, or intramuscularly.
- the invention provides compositions for parenteral administration which comprise a solution of the immunogenic peptides dissolved or suspended in an acceptable carrier, preferably an aqueous carrier.
- an aqueous carrier e.g., water, buffered water, 0.4% saline, 0.3% glycine, hyaluronic acid and the like.
- These compositions may be sterilized by conventional, well known sterilization techniques, or may be sterile filtered.
- compositions may be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile solution prior to administration.
- the compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions, such as buffering agents, tonicity adjusting agents, wetting agents and the like, for example, sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, sorbitan monolaurate, triethanolamine oleate, etc.
- nontoxic solid carriers include, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium carbonate, and the like.
- a pharmaceutically acceptable nontoxic composition is formed by incorporating any of the normally employed excipients, such as those carriers previously listed, and generally 10-95% of active ingredient, that is, one or more peptides of the invention, and more preferably at a concentration of 25%-75%.
- the peptide compositions are intended to induce an immune response to the peptides.
- compositions and methods of administration suitable for maximizing the immune response are preferred.
- peptides may be introduced into a host, including humans, linked to a carrier or as a homopolymer or heteropolymer of active peptide units.
- the a “cocktail” of polypeptides can be used.
- a mixture of more than one polypeptide has the advantage of increased immunological reaction and, where different peptides are used to make up the polymer, the additional ability to induce antibodies to a number of epitopes.
- polypeptides comprising sequences from extracellular regions of ⁇ and ⁇ chains may be used in combination.
- Useful carriers include, e.g., KLH, thyroglobulin, albumins such as human serum albumin, tetanus toxoid, polyamino acids such as poly(lysine:glutamic acid), influenza, hepatitis B virus core protein, hepatitis B virus recombinant vaccine and the like.
- polypeptides may be derived from self Chemokine receptor molecules expressed in the patient, they can induce an immune response. In some instances, the immune response to the self polypeptide may not be sufficiently strong. In these instances, it may be necessary to break tolerance to the polypeptide.
- the compositions may comprise one or more of the foreign polypeptides that are sufficiently similar to the self polypeptides to induce an immune response against both the foreign and self polypeptides (see, Mamula et al. J. Immunol. 149:789-795 (1992).
- Suitable proteins include synthetic polypeptides designed for this purpose or polypeptide sequences from homologous proteins from natural sources, such as proteins encoded by a different allele at the same locus as the self polypeptide.
- compositions also include an adjuvant.
- adjuvants include incomplete Freund's adjuvant, alum, aluminum phosphate, aluminum hydroxide, N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine (CGP 11637, referred to as nor-MDP), N-acetylmuramyl-Lalanyl-D-isoglutaminyl-L-alanine-2-(1′-2′-dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)-ethylamine (CGP 19835A, referred to as MTP-PE), and RIBI, which contains three components extracted from bacteria, monophosphoryl lipid A, trehalose dimycolate and cell wall
- a particularly useful adjuvant and immunization schedule are described in Kwak et al. New Eng. J Med. 327-1209-1215 (1992).
- the immunological adjuvant described there comprises 5% (wt/vol) squalene, 2.5% Pluronic L121 polymer and 0.2 % polysorbate in phosphate buffered saline.
- the concentration of immunogenic peptides of the invention in the pharmaceutical formulations can vary widely, i.e. from less than about 0.1%, usually at or at least about 2% to as much as 20% to 50% or more by weight, and will be selected primarily by fluid volumes, viscosities, etc., in accordance with the particular mode of administration selected.
- the peptides of the invention can also be expressed by attenuated viral hosts, such as vaccinia or fowlpox.
- This approach involves the use of vaccinia virus as a vector to express nucleotide sequences that encode the peptides of the invention.
- the recombinant vaccinia virus Upon introduction into a host, the recombinant vaccinia virus expresses the immunogenic peptide, and thereby elicits an immune response.
- Vaccinia vectors and methods useful in immunization protocols are described in, e.g., U.S. Pat. No. 4,722,848.
- Another vector is BCG (Bacille Calnette Guerin). BCG vectors are described in Stover et al.
- DNA encoding one or more of the peptides of the invention can also be administered to the patient. This approach is described, for instance, in Wolff et. al., Science 247:1465-1468 (1990) as well as U.S. Pat. Nos. 5,580,859 and 5,589,466.
- the peptides may also be encapsulated, introduced into the lumen of liposomes, prepared as a colloid, or other conventional techniques may be employed which provide an extended serum half-life of the peptides.
- liposomes as described in, e.g., Szoka et al., Ann. Rev. Biophys. Bioeng. 9:467 (1980), U.S. Pat. Nos. 4,235,871, 4,501,728 and 4,837,028.
- peptides or antibodies of the invention can also be used for diagnostic purposes. For instance, peptides can be used to screen for autoantibodies to ensure that the vaccination has been effective. Antibodies can be used to detect the presence of particular Chemokine receptor molecules associated with disease.
- a stable line transfectant of NSO-1 cells expressing the cDNA for human CXCR3 was prepared according to standard techniques. The surface expression of hu-CXCR3 on the transfectants compared to untransfected parent NSO-1 cells was confirmed by FACS staining using mouse anti-human CXCR3 monoclonal antibody (R&D systems).
- the CXCR3 transfectant cells were cultured with either human IP-10, or the mouse anti-human CXCR3 antibody, and the physiological response of the cells was measured using a microphysiometer. This machine measures changes in the pH of the extracellular medium of the cell cultures which result from ligand receptor binding on the cell surface. These extracellular acidification rate measurements have previously been used as markers of antigen specific T cell activation and T cell epitope identification.
- the current assay is used to provide a biological read out for the identification of chemokine or chemokine receptor peptides involved in binding to IP- 10 or agonistic anti-CXCR3 antibody.
- This example describes synthesis of human CXCR3 derived peptides.
- FIG. 2 A schematic representation of the surface portion of human CXCR3 is given in FIG. 2.
- the receptor has 4 surface portions, 4 intracellular portions and seven transmembrane portions.
- the surface portions were designated starting from N-terminus as SP-1, SP-2, SP-3 and SP-4.
- the peptides shown in Table 1 derived from these four surface portions were prepared by solid phase peptide synthesis.
- the names of the peptides are based on the surface portion of CXCR3 from which they were derived.
- SP-1-1 means this peptide was derived from the first portion of the CXCR3 protein.
- mice (6-8 weeks old) were obtained from Jackson Laboratories. They were kept in quarantine for two weeks. These mice get EAE when immunized with a peptide from proteolipid protein (PLP).
- PLP proteolipid protein
- the peptide sequence used for the immunization of these mice is PLP 139-151 and is amidated at the C terminus (HSLGWLGHPDKF-NH2).
- induction of the disease is considered Day 0.
- the mice were vaccinated with Human CXCR3S-P4-1 peptide mixed with complete Freund's Adjuvant.
- mice were bled at week 0 and week 5 and serum was tested by ELISA for the presence of antibodies against the human CXCR3 SP-4-1 peptide.
- the SP4-1 peptide dissolved in 0.1 M sodium bicarbonate buffer was plated on a 96-well ELISA plate overnight. The nonspecific binding sites on the plate were coated with 0.1% bovine serum albumin solution in PBS. The wells were washed and serum (diluted in PBS) was added to the wells and incubated at room temperature for 1.5 hours. The wells were then washed and HRP conjugated anti-mouse immunoglobulin antibody was used to detect the presence of anti-SP4-1 antibodies). The results of this ELISA clearly indicate that the SP4-1 treated mice show an antibody response against this peptide.
- Sp4-1 was administered with CFA at 21 days and 14 days before induction of EAE as described above (FIG. 3). The results are shown in FIG. 4. There it can be seen that while most of the untreated and CFA treated mice showed clinical symptoms of EAE, 7 out of 8 mice treated with SP4-1 in CFA showed no clinical symptoms.
Abstract
The present invention provides immunogenic oligopeptides derived from the chemokine receptor protein for use in compositions and methods for the treatment, and prevention of inflammatory responses.
Description
- The present invention relates to novel compositions and methods for inhibiting inflammatory responses associated with autoimmune diseases. In particular, it relates to vaccination with peptides from the extracellular regions of chemokine receptor molecules.
- Chemokines constitute a family of small molecular weight cytokines that are produced in inflammation and regulate leukocyte recruitment. These molecules are ligands for seven transmembrane G protein linked receptors that induce a signaling cascade costimulation for T cell activation in addition to participating in transendothelial migration of leukocytes (Oppenheim et al. Ann. Rev. Immunol. 9:617-648 (1991), Premback et al. Nat. Med. 2:1174-1178 (1996)). Two subfamilies of chemokines, referred to as CC and CXC, have been discovered. CC and CXC chemokines are distinct from each other in their N terminal amino acid sequence which starts either with cysteine-cysteine or cysteine-X-cysteine where X is typically another L-amino acid. They are also distinct in their binding pattern to their receptors. For example, the CC chemokines bind to CC receptors and not to CXC receptors and vice versa.
- Different chemokines regulate the trafficking of distinct populations of hemopoietic cells by activating specific 7-transmembrane receptors expressed by these cells (Baggiolini et al. Adv. Immunol. 55:97-179 (1994); Gerard et al. Curr. Opin. Immunol.6:140-145 (1994)). Recent publications indicate that the Th1 and Th2 subsets of regulatory T cells are uniquely characterized by the chemokine receptors CXCR3 and CCR3, respectively (Sallusto, et al. J. Exp. Med. 187:875-883 (1998); Bonecchi, et al. J Exp. Med. 187:129-134 (1998); Qin, et al. J. Clin Invest. 101:746-754 (1998)). Several studies have correlated the expression of three specific chemokines, IP-10, RANTES, and MCP-1, produced by astrocytes in the CNS with the presence of inflammatory infiltration within this tissue during the early phase of EAE (Ransohoff, et al. FASEB J. 7:592-600 (1993); Glabinski et al. Am. J. Pathol. 150:617-630 (1995) Godiska, et al. J. Neuroimmunol. 58:167-176 (1995); and Eng et al. Neurchem. Res. 21:511-525 (1996)). While all three chemokines have been shown to be capable of recruiting T lymphocytes in certain experimental models, IP-10 has been demonstrated to be specific for this lineage of hemopoietic cells (Taub et al. J. Exp. Med. 177:1809-1814 (1993)); Carr, et al. Proc. Natl. Acad. Sci. USA 91:3652-3656 (1994); and Farber, J. Leukoc. Biol. 61:246-257 (1997). MBP-immunized rats intrathecaly infused with an antisense phosphorothioate oligonucleotide to crg-2 (the murine homologue of human IP-10) show reduced disease clinical score of EAE (Wojcik, et al. J. Pharmacol. Exp. Ther. 278:404-410 (1996)). In addition, higher expression of some of the chemokine receptors such as CXCR3 on IL2 activated human T lymphocytes and not on resting T lymphocytes has been demonstrated (Loetscher et al. J Exp. Med. 184:963-969 (1996)).
- Multiple sclerosis (MS) is a T cell-dependent autoimmune disease caused by localized demyelination in the central nervous system (CNS), with only limited therapeutic options available to patients. Extensive investigation has indicated that these autoreactive T lymphocytes frequently, though not always, express the Th1 phenotype of high level production of IFNg, IL-2 and TNFa, with little to no IL-4, IL-5 and IL-10.
- Current therapeutics for autoimmune diseases, such as MS, involve the use of antiinflammatory agents or general immunosuppressants. Prior art methods for controlling autoimmune disease fail to provide a simple self-mediated method for specifically eliminating inflammatory responses mediated by chemokines associated with the autoimmune responses. The present invention addresses these and other needs.
- The present invention provides methods of inducing an immune response against a chemokine receptor molecule in a patient. The methods comprise administering to the patient an immunologically effective amount of a pharmaceutical composition comprising an adjuvant and an immunogenic chemokine receptor polypeptide from a extracellular region of a chemokine receptor molecule, for example CXCR3.
- The immunogenic peptides are preferably conformationally constrained, for example by cyclization. The length of the immunogenic peptide is not critical to the invention. Typically, the peptide consists of between about 10 and about 50 residues, more often between about 15 and about 30 residues. Exemplary immunogenic peptides of the invention include MVLEVSDHQVLNDAEVAALL, ENFSSSYDYGENESDSCCTS, PPCPQDFSLNFDRAFLPA, DAAVQWVFGSGLCKV, SAHHDERLNATHCQYN, FPQVGRTALRVLQLVAG, and DILMDLGALARNCGRESRVDVAKS.
- The immunogenic peptides can be administered by any of a number of means. Typically they are administered parenterally. The adjuvant can be, for example, alum.
- In preferred embodiments, the method are used to inhibit recruitment of T cells to inflammation sites in a patient. Typically the inflammatory response is associated with an autoimmune disease, such as multiple sclerosis.
- The invention also provides pharmaceutical compositions suitable for use in the above methods.
- The term “peptide” is used interchangeably with “oligopeptide” or “polypeptide” in the present specification to designate a series of residues, typically L-amino acids, connected one to the other typically by peptide bonds between the α-amino and carbonyl groups of adjacent amino acids.
- The term “cyclic peptide” refers to peptides in which the N-terminal residue is linked to the C-terminal residue either directly or through an intermediate. Examples of links between the two residues include disulfide bonds and thioether linkages as described below.
- An “immunogenic chemokine receptor polypeptide” of the present invention is a polypeptide capable of eliciting an immune response against a chemokine receptor molecule associated with inflammation in autoimmune responses in a patient, such as multiple sclerosis. As set forth in more detail below, the sequence of residues in the polypeptide will be identical to or substantially identical to a polypeptide sequence in a chemokine receptor molecule. Thus, a polypeptide of the invention that has a sequence “from a extracellular region of a chemokine receptor molecule” is polypeptide that has a sequence either identical to or substantially identical to the naturally occurring chemokine receptor amino acid sequence of the region.
- As used herein a “extracellular region” of a chemokine receptor molecule is a region of the molecule which is exposed on the surface of a cell expressing the native molecule. FIG. 1 provides a schematic of the extracellular domains of the human CXCR3 molecule. This molecule has four extracellular regions designated as SP-1, SP-2, SP-3 and SP-4, starting from the N-terminus.
- As used herein, the term “adjuvant” refers to any substance which, when administered with or before an antigen, increases and/or qualitatively affects the immune response against the antigen in terms of antibody formation and/or the cell-mediated response. Exemplary adjuvants for use in the present invention are provided below.
- The phrases “isolated” or “biologically pure” refer to material which is substantially or essentially free from components which normally accompany it as found in its native state. Thus, the chemokine receptor polypeptides of this invention do not contain materials normally associated with their in situ environment, e.g., other surface proteins on T cells. Even where a protein has been isolated to a homogenous or dominant band, there are trace contaminants in the range of 5-10% of native protein which co-purify with the desired protein. Isolated polypeptides of this invention do not contain such endogenous co-purified protein.
- The term “residue” refers to an amino acid or amino acid mimetic incorporated in a oligopeptide by an amide bond or amide bond mimetic.
- FIG. 1 shows acidification rate changes due to the binding of anti-human CXCR3 Mab or P-10 to CXCR3-NSO transfectants. 5X105 CXCR3-NSO transfectant cells and untransfected “BONZO-NSO” cells (negative control) were spotted in the microphysiometer chambers along with agarose and 1, 5, 10 mglml anti-CXCR3 (FIG 1 a) or IP-10 (FIG 1 b) was pumped for 10 min. There is a dose dependent increase in the acidification rates with anti-CXCR3 in NSO-CXCR3 transfectant cells. Untransfected BONZO-NSO cells did not show any change in acidification rate changes either with the anti-CXCR3 antibody, or IP-10. The arrow indicates the time that ligands were added to the cells.
- FIG. 2 shows the structure of the seven transmembrane G-protein coupled human CXCR3. Only amino acids in the extracellular domains are given
- FIG. 3 is a schematic of the experiments in which peptides vaccines of the invention were used to prevent EAE in mice.
- FIG. 3 shows the results of experiments in which peptides vaccines of the invention were used to prevent EAE in mice.
- The present invention provides immunogenic polypeptides derived from chemokine receptor protein sequences for use in compositions and methods for the treatment and prevention of inflammatory responses. The polypeptides are capable of inducing an immune response against chemokine receptor molecules which mediate inflammatory responses associated with various diseases. In preferred embodiments the polypeptides of the invention are conformationally constrained (e.g., cyclized) and derived from extracellular regions of human CXCR3. Immunization with the polypeptides of the invention provides a specific immune response to particular chemokine receptors and results in the specific inhibition of the inflammatory responses mediated by these molecules.
- The methods can be used to treat any inflammatory response mediated by chemokines. In particular, the methods are useful for treatment of autoimmune diseases, such as multiple sclerosis. Multiple sclerosis (MS), a human demyelinating disease which afflicts 600,000 individuals worldwide, results from damage of the myelin sheath of oligodendroglial cells in the Central Nervous System (CNS). Although the pathogenesis and etiology of MS have not yet been established, it is widely believed that the disease has an immunological basis and that both genetic and environmental factors make a contribution to the pathogenesis. The central mediator of autoimmune attack is believed to be host CD4+T cells specific for one or more autoantigens in the CNS, with subsequent production of an array of tissue-destructive inflammatory mediators following autoantigen-activation of these cells. Indeed, immunohistochemical analysis of the focal plaques of demyelination which occur in the brains of MS patients as a consequence of MS pathology have revealed the presence of CD4+T cells infiltrating these plaques.
- Improved understanding of the immunopathological mechanisms underlying MS has developed from the study of experimental models of demyelination. The most commonly used model, experimental allergic encephalomyelitis (EAE), is an autoimmune inflammatory disorder of genetically susceptible mice that is mediated by autoantigen-specific CD4+MHC class II restricted T cells. In susceptible SJL/J mice, the disease can display a relapsing-remitting clinical course of paralysis, which makes it an ideal system to study the efficacy of various immunoregulatory strategies both in the prevention and treatment of disease.
- The current invention is focused not on the cytokine-producing phenotype of autoreactive T cells in this disease setting, but on their trafficking from the host circulation to the site of pathology, for example within the CNS in the case of MS. As noted above, hemopoietic cell migration is regulated by chemokines.
- In some embodiments, the invention provides peptide vaccines against the 7-transmembrane chemokine receptor designated CXCR3. Consistent with the chemotactic fingerprint of IP-10, CXCR3 is expressed exclusively on activated effector T lymphocytes. Exemplary peptides of the invention include peptides derived from the extracellular domains of the CXCR3 protein are presented in Table 1.
- In preferred embodiments, the peptides of the invention are cyclized. Methods for cyclizing peptides are described in detail below. In those cases in which the peptides are cyclized by disulfide linkages, one of skill will recognize that the peptides will further comprise cysteine residues either within the peptide or at each terminus.
- Polypeptides suitable for use in the present invention can be obtained in a variety of ways. Conveniently, they can be synthesized by conventional techniques employing automatic synthesizers, such as the Beckman, Applied Biosystems, or other commonly available peptide synthesizers using well known protocols. They can also be synthesized manually using techniques well known in the art. See, e.g. Stewart and Young, Solid Phase Peptide Synthesis, (Rockford, Ill., Pierce), 2d Ed. (1984).
- Alternatively, DNA sequences which encode the particular chemokine receptor polypeptide may be cloned and expressed to provide the peptide. Nucleic acid molecules encoding chemokine receptors are known in the art and sequences of such genes are available, for instance, from GenBank (see, e.g., GenBank Accession Nos. HSU83326 HSU97123, and AF005058).
- Standard techniques can be used to screen cDNA libraries to identify sequences encoding the desired sequences (see, Sambrook et al., Molecular Cloning—A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1989). Fusion proteins (those consisting of all or part of the amino acid sequences of two or more proteins) can be recombinantly produced. In addition, using in vitro mutagenesis techniques, unrelated proteins can be mutated to comprise the appropriate sequences.
- Chemokine receptor proteins from a variety of natural sources are also conveniently isolated using standard protein purification techniques. Peptides can be purified by any of a variety of known techniques, including, for example, reverse phase high-performance liquid chromatography (HPLC), ion-exchange or immunoaffinity chromatography, separation by size, or electrophoresis (See, generally, Scopes, R., Protein Purification, Springer-Verlag, N.Y. (1982)).
- It will be understood that the immunogenic chemokine receptor polypeptides of the present invention may be modified to provide a variety of desired attributes, e.g., improved pharmacological characteristics, while increasing or at least retaining substantially all of the biological activity of the unmodified peptide. For instance, the peptides can be modified by extending, decreasing the amino acid sequence of the peptide. Substitutions with different amino acids or amino acid mimetics can also be made.
- The peptides employed in the subject invention need not be identical to peptides disclosed in the Example section, below, so long as the subject peptides are able to induce an immune response against the desired chemokine receptor molecule. Thus, one of skill will recognize that a number of conservative substitutions (described in more detail below) can be made without substantially affecting the activity of the peptide.
- Single amino acid substitutions, deletions, or insertions can be used to determine which residues are relatively insensitive to modification. Substitutions are preferably made with small, relatively neutral moieties such as Ala, Gly, Pro, or similar residues. The effect of single amino acid substitutions may also be probed using D-amino acids. The number and types of residues which are substituted or added depend on the spacing necessary between essential contact points and certain functional attributes which are sought (e.g., hydrophobicity versus hydrophilicity). Increased immunogenicity may also be achieved by such substitutions, compared to the parent peptide. In any event, such substitutions should employ amino acid residues or other molecular fragments chosen to avoid, for example, steric and charge interference which might disrupt binding.
- The substituting amino acids, however, need not be limited to those naturally occurring in proteins, such as L-α-amino acids, or their D-isomers. The peptides may be substituted with a variety of moieties such as amino acid mimetics well known to those of skill in the art.
- The individual residues of the immunogenic chemokine receptor polypeptides can be incorporated in the peptide by a peptide bond or peptide bond mimetic. A peptide bond mimetic of the invention includes peptide backbone modifications well known to those skilled in the art. Such modifications include modifications of the amide nitrogen, the α-carbon, amide carbonyl, complete replacement of the amide bond, extensions, deletions or backbone crosslinks. See, generally, Spatola, Chemistry and Biochemistry of Amino Acids, Peptides and Proteins, Vol. VII (Weinstein ed., 1983). Several peptide backbone modifications are known, these include, ψ[CH2S], ψ[CH2NH], ψ[CSNH2], ψ[NHCO], ψ[COCH2] and ψ(E) or (Z) CH=CH]. The nomenclature used above, follows that suggested by Spatola, above. In this context, ψ indicates the absence of an amide bond. The structure that replaces the amide group is specified within the brackets.
- Amino acid mimetics may also be incorporated in the peptides. An “amino acid mimetic” as used here is a moiety other than a naturally occurring amino acid that conformationally and functionally serves as a substitute for an amino acid in a polypeptide of the present invention. Such a moiety serves as a substitute for an amino acid residue if it does not interfere with the ability of the peptide to illicit an immune response against the appropriate chemokine receptor molecule. Amino acid mimetics may include non-protein amino acids, such as β-γ-δ-amino acids, β-γ-δ-imino acids (such as piperidine-4-carboxylic acid) as well as many derivatives of L-α-amino acids. A number of suitable amino acid mimetics are known to the skilled artisan, they include cyclohexylalanine, 3-cyclohexylpropionic acid, L-adamantyl alanine, adamantylacetic acid and the like. Peptide mimetics suitable for peptides of the present invention are discussed by Morgan and Gainor, (1989) Ann. Repts. Med. Chem. 24:243-252/.
- As noted above, the peptides employed in the subject invention need not be identical, but may be substantially identical, to the corresponding sequence of the target chemokine receptor molecule. Therefore, the peptides may be subject to various changes, such as insertions, deletions, and substitutions, either conservative or non-conservative, where such changes might provide for certain advantages in their use. The polypeptides of the invention can be modified in a number of ways so long as they comprise a sequence substantially identical (as defined below) to a sequence in the target region of the chemokine receptor molecule.
- Alignment and comparison of relatively short amino acid sequences (less than about 30 residues) is typically straightforward. Comparison of longer sequences may require more sophisticated methods to achieve optimal alignment of two sequences. Optimal alignment of sequences for aligning a comparison window may be conducted by the local homology algorithm of Smith and Waterman (1981) Adv. Appl. Math. 2:482, by the homology alignment algorithm of Needleman and Wunsch (1970) J. Mol. Biol. 48:443, by the search for similarity method of Pearson and Lipman (1988) Proc. Natl. Acad. Sci. (USA) 85:2444, by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package Release 7.0, Genetics Computer Group, 575 Science Dr., Madison, Wis.), or by inspection, and the best alignment (i.e., resulting in the highest percentage of sequence similarity over the comparison window) generated by the various methods is selected.
- The term “sequence identity” means that two polynucleotide sequences are identical (i.e., on a nucleotide-by-nucleotide basis) over a window of comparison. The term “percentage of sequence identity” is calculated by comparing two optimally aligned sequences over the window of comparison, determining the number of positions at which the identical residues occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison (i.e., the window size), and multiplying the result by 100 to yield the percentage of sequence identity.
- As applied to polypeptides, the term “substantial identity” means that two peptide sequences, when optimally aligned, such as by the programs GAP or BESTFIT using default gap weights, share at least 80 percent sequence identity, preferably at least 90 percent sequence identity, more preferably at least 95 percent sequence identity or more (e.g., 99 percent sequence identity). Preferably, residue positions which are not identical differ by conservative amino acid substitutions. Conservative amino acid substitutions refer to the interchangeability of residues having similar side chains. For example, a group of amino acids having aliphatic side chains is glycine, alanine, valine, leucine, and isoleucine; a group of amino acids having aliphatic-hydroxyl side chains is serine and threonine; a group of amino acids having amide-containing side chains is asparagine and glutamine; a group of amino acids having aromatic side chains is phenylalanine, tyrosine, and tryptophan; a group of amino acids having basic side chains is lysine, arginine, and histidine; and a group of amino acids having sulfur-containing side chains is cysteine and methionine. Preferred conservative amino acids substitution groups are: valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, and asparagine-glutamine.
- The polypeptides of the invention typically comprise at least about 10 residues and more preferably at least about 15 residues from the extracellular domain of a chemokine receptor. In certain embodiments the peptides will not exceed about 50 residues and typically will not exceed about 30 residues. For instance, the peptides described below consist of about 15 to about 25 residues.
- In the preferred embodiments of the invention, the immunogenic peptides are conformationally constrained. Means for achieving this are well known in the art (see, e.g., Hruby and Bonner in Methods in Molecular Biology, Volume 35: Peptide Synthesis Protocols Pennington and Dunn eds (Humana Press, Totowa, N.J., 1994). A preferred means for preparing conformationally constrained peptides is through cyclization. Any method commonly used to produce cyclized oligopeptides can be used to produce the peptides of the invention. For example, in certain embodiments the peptides will include cysteine residues at both termini, which allow the production of cyclic peptides through disulfide linkages. Treatment of a such a peptide with an oxidizing agent such as oxygen, iodine or similar agent will produce a cyclic peptide which may be further purified using chromatographic or other methods of chemical purification. Construction of cyclic peptides can also be accomplished through thioether linkages. For instance, N-bromoacetyl-derivatized peptides can be reacted with sulfhydryl-containing residues, such as cysteine. Cyclization occurs by reaction of the free sulfhydryl of cysteine in the peptide with the bromoacetyl group to form a thioether linkage (Robey et al., Anal. Biochem. 177:373-7 (1989) and U.S. Pat. No. 5,066,716).
- Other methods of constructing cyclic peptides are known to those skilled in the art. These include side chain-side chain, side chain-main chain and main chain-main chain cyclizations. In addition, linkers can be used to join the amino and carboxyl termini of a peptide. The linker is capable of forming covalent bonds to both the amino and carboxyl terminus. Suitable linkers are well known to those of skill in the art and include, but are not limited to, straight or branched-chain carbon linkers, heterocyclic carbon linkers, or peptide linkers. The linkers may be joined to the carboxyl and amino terminal amino acids through their side groups (e.g., through a disulfide linkage to cysteine) or through the alpha carbon amino and carboxyl groups of the terminal amino acids.
- For a general discussion of suitable methods for cyclization see, Hruby and Bonner in Methods in Molecular Biology, Volume 35: Peptide Synthesis Protocols Pennington and Dunn eds (Humana Press, Totowa, N.J., 1994). For instance, cyclizations may include formation of carba analogs and thioethers (Lebl et al. in Peptides 1986 Proceedings of the 19th European Peptide Symposium pp. 341-344; Robey et al., Anal Biochem. 177:373-7 (1989) and U.S. Pat. No. 5,066,716), bis-thioethers (Mosberg et al. JACS 107:2986-2987 (1985)), azopeptides (Siemion et al. Mol. Cell. Biochem. 34: (1991)), and other cyclic structures, such as bridging structures (Charpentier, M., et al., J Med. Chem. 32(6):1184-1190 (1989), Thaisrivongs, S., et al., J. Med. Chem. 34(4):127 (1991) and Ozeki, E., et al., Int. J. Peptide Protein Res. 34:111 (1989)). Cyclization from backbone-to-backbone positions may also be used.
- Bridging is a special type of cyclization in which distant sites in a peptide are brought together using separate bridging molecules or fragments. Bridging molecules may include, for example, succinic anhydride molecules (Charpentier, B., et al., supra), and carboxymethylene fragments (Thaisrivongs, S., et al., supra). Bridging by metals can also be used (Ozeki, E., et al., supra).
- In some embodiments, the peptides include two or more cystine residues. The cystines can be substituted or added within the peptide or at either terminus. The position of the cystines is not critical so long as disulfide linkages can form between them which allow the production of cyclic peptides. For example, treatment of such a peptide with an oxidizing agent such as oxygen, iodine or similar agent will produce a cyclic peptide which may be further purified using chromatographic or other methods of chemical purification.
- In addition to use of peptides, antibodies raised against peptides of the invention can be used to inhibit inflammatory responses. Antibodies can be raised to the peptides of the present invention using techniques well known to those of skill in the art. Anti-idiotypic antibodies can also be generated. The following discussion is presented as a general overview of the techniques available; however, one of skill will recognize that many variations upon the following methods are known.
- A number of immunogens can be used to produce antibodies specifically reactive with the peptides. For instance, the entire chemokine receptor molecule or fragments containing the desired sequence can be used. Synthetic peptides as disclosed here can be used either in linear form or cyclized.
- Methods of producing polyclonal antibodies are known to those of skill in the art. In brief, an immunogen (antigen), preferably a purified polypeptide, a polypeptide coupled to an appropriate carrier (e.g., GST, keyhole limpet hemanocyanin, etc.), or a polypeptide incorporated into an immunization vector such as a recombinant vaccimia virus (see, U.S. Pat. No. 4,722,848) is mixed with an adjuvant and animals are immunized with the mixture. The animal's immune response to the immunogen preparation is monitored by taking test bleeds and determining the titer of reactivity to the polypeptide of interest. When appropriately high titers of antibody to the immunogen are obtained, blood is collected from the animal and antisera are prepared. Further fractionation of the antisera to enrich for antibodies reactive to the polypeptide is performed where desired (see, e.g., Coligan (1991) Current Protocols in Immunology Wiley/Greene, N.Y.; and Harlow and Lane (1989) Antibodies: A Laboratory Manual Cold Spring Harbor Press, N.Y.).
- In some instances, it is desirable to prepare monoclonal antibodies from various mammalian hosts, such as mice, rodents, primates, humans, etc. Description of techniques for preparing such monoclonal antibodies are found in, e.g., Stites et al. (eds.) Basic and Clinical Immunology (4th ed.) Lange Medical Publications, Los Altos, Calif., and references cited therein; Harlow and Lane, Supra; Goding (1986) Monoclonal Antibodies: Principles and Practice (2d ed.) Academic Press, New York, N.Y.; and Kohler and Milstein (1975) Nature 256:495-497. Summarized briefly, this method proceeds by injecting an animal with an immunogen. The animal is then sacrificed and cells taken from its spleen, which are fused with myeloma cells. The result is a hybrid cell or “hybridoma” that is capable of reproducing in vitro. The population of hybridomas is then screened to isolate individual clones, each of which secrete a single antibody species to the immunogen. In this manner, the individual antibody species obtained are the products of immortalized and cloned single B cells from the immune animal generated in response to a specific site recognized on the immunogenic substance.
- Alternative methods of immortalization include transformation with Epstein Barr Virus, oncogenes, or retroviruses, or other methods known in the art. Colonies arising from single immortalized cells are screened for production of antibodies of the desired specificity and affinity for the antigen, and yield of the monoclonal antibodies produced by such cells is enhanced by various techniques, including injection into the peritoneal cavity of a vertebrate (preferably mammalian) host. Specific monoclonal and polyclonal antibodies will usually bind with a KD of at least about 0.1 mM, more usually at least about 50 μM, and most preferably at least about 1 μM or better.
- Other suitable techniques involve selection of libraries of recombinant antibodies in phage or similar vectors (see, e.g., Huse et al. (1989) Science 246:1275-1281; and Ward, et al. (1989) Nature 341:544-546; and Vaughan et al (1996) Nature Biotechnology, 14:309-314).
- Frequently, the peptides and antibodies of the invention will be labeled by joining, either covalently or non-covalently, a substance which provides for a detectable signal. A wide variety of labels and conjugation techniques are known and are reported extensively in both the scientific and patent literature. Suitable labels include radionucleotides, enzymes, substrates, cofactors, inhibitors, fluorescent moieties, chemiluminescent moieties, magnetic particles, and the like. Patents teaching the use of such labels include U.S. Pat. Nos. 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149; and 4,366,241. Also, recombinant immunoglobulins may be produced. See, Cabilly, U.S. Pat. No. 4,816,567; and Queen et al. (1989) Proc. Nat'l Acad. Sci. USA 86: 10029-10033.
- The antibodies of this invention can also be administered to an organism (e.g., a human patient) for therapeutic purposes (e.g., to inhibit an autoimmune response). Antibodies administered to an organism other than the species in which they are raised are often immunogenic. Thus, for example, murine antibodies administered to a human often induce an immunologic response against the antibody (e.g., the human anti-mouse antibody (HAMA) response) on multiple administrations. The immunogenic properties of the antibody are reduced by altering portions, or all, of the antibody into characteristically human sequences thereby producing chimeric or human antibodies, respectively.
- Chimeric antibodies are immunoglobulin molecules comprising a human and non-human portion. More specifically, the antigen combining region (or variable region) of a humanized chimeric antibody is derived from a non-human source (e.g., murine) and the constant region of the chimeric antibody (which confers biological effector function to the immunoglobulin) is derived from a human source. The chimeric antibody should have the antigen binding specificity of the non-human antibody molecule and the effector function conferred by the human antibody molecule. A large number of methods of generating chimeric antibodies are well known to those of skill in the art (see, e.g., U.S. Pat. Nos: 5,502,167, 5,500,362, 5,491,088, 5,482,856, 5,472,693, 5,354,847, 5,292,867, 5,231,026, 5,204,244, 5,202,238, 5,169,939, 5,081,235, 5,075,431, and 4,975,369). An alternative approach is the generation of humanized antibodies by linking the CDR regions of non-human antibodies to human constant regions by recombinant DNA techniques. See Queen et al., Proc. Natl. Acad. Sci. USA 86:10029-10033 (1989) and WO 90/07861.
- In one preferred embodiment, recombinant DNA vector is used to transfect a cell line that produces an antibody against a peptide of the invention. The novel recombinant DNA vector contains a “replacement gene” to replace all or a portion of the gene encoding the immunoglobulin constant region in the cell line (e.g., a replacement gene may encode all or a portion of a constant region of a human immunoglobulin, or a specific immunoglobulin class), and a “target sequence” which allows for targeted homologous recombination with immunoglobulin sequences within the antibody producing cell.
- In another embodiment, a recombinant DNA vector is used to transfect a cell line that produces an antibody having a desired effector function, (e.g., a constant region of a human immunoglobulin) in which case, the replacement gene contained in the recombinant vector may encode all or a portion of a region of an antibody and the target sequence contained in the recombinant vector allows for homologous recombination and targeted gene modification within the antibody producing cell. In either embodiment, when only a portion of the variable or constant region is replaced, the resulting chimeric antibody may define the same antigen and/or have the same effector function yet be altered or improved so that the chimeric antibody may demonstrate a greater antigen specificity, greater affinity binding constant, increased effector function, or increased secretion and production by the transfected antibody producing cell line, etc.
- In another embodiment, this invention provides for fully human antibodies. Human antibodies consist entirely of characteristically human polypeptide sequences. The human antibodies of this invention can be produced in using a wide variety of methods (see, e.g., Larrick et al., U.S. Pat. No. 5,001,065). In one preferred embodiment, the human antibodies of the present invention are produced initially in trioma cells. Genes encoding the antibodies are then cloned and expressed in other cells, particularly, nonhuman mammalian cells. The general approach for producing human antibodies by trioma technology has been described by Ostberg et al. (1983), Hybridoma 2:361-367, Ostberg, U.S. Pat. No. 4,634,664, and Engelman et al., U.S. Pat. No. 4,634,666. The antibody-producing cell lines obtained by this method are called triomas because they are descended from three cells; two human and one mouse. Triomas have been found to produce antibody more stably than ordinary hybridomas made from human cells.
- Formulation and Administration
- The peptides or antibodies (typically monoclonal antibodies) of the present invention and pharmaceutical compositions thereof are useful for administration to mammals, particularly humans, to treat and/or prevent deleterious immune inflammatory responses, particularly those associated with autoimmune responses. Over 30 autoimmune diseases are presently known, including myasthenia gravis (MG), multiple sclerosis (MS), systemic lupus erythematosis (SLE), rheumatoid arthritis (RA), insulin-dependent diabetes mellitus (IDDM), and the like. Suitable formulations are found in Remington's Pharmaceutical Sciences, Mack Publishing Company, Philadelphia, PA, 17th ed. (1985).
- The immunogenic peptides or antibodies of the invention are administered prophylactically or to an individual already suffering from the disease. The peptide compositions are administered to a patient in an amount sufficient to elicit an effective immune response to the chemokine receptor molecule from which the peptides are derived. An effective immune response is one that inhibits recruitment of T cells to sites of inflammation. An amount adequate to accomplish this is defined as “therapeutically effective dose” or “immunogenically effective dose.” Amounts effective for this use will depend on, e.g., the peptide composition, the manner of administration, the stage and severity of the disease being treated, the weight and general state of health of the patient, and the judgment of the prescribing physician, but generally range for the initial immunization (that is for therapeutic or prophylactic administration) from about 0.1 mg to about 1.0 mg per 70 kilogram patient, more commonly from about 0.5 mg to about 0.75 mg per 70 kg of body weight. Boosting dosages are typically from about 0.1 mg to about 0.5 mg of peptide using a boosting regimen over weeks to months depending upon the patient's response and condition. A suitable protocol would include injection at
time - It must be kept in mind that the peptides and compositions of the present invention may generally be employed in serious disease states, that is, life-threatening or potentially life threatening situations. In such cases, in view of the minimization of extraneous substances and the relative nontoxic nature of the peptides, it is possible and may be felt desirable by the treating physician to administer substantial excesses of these peptide compositions.
- For therapeutic use, administration should begin at the first sign of autoimmune disease. This is followed by boosting doses until at least symptoms are substantially abated and for a period thereafter. In some circumstances, loading doses followed by boosting doses may be required. The resulting immune response helps to cure or at least partially arrest symptoms and/or complications. Vaccine compositions containing the peptides are administered prophylactically to a patient susceptible to or otherwise at risk of the disease to elicit an immune response against the target Chemokine receptor antigen.
- The pharmaceutical compositions (containing either peptides or antibodies) are intended for parenteral or oral administration. Preferably, the pharmaceutical compositions are administered parenterally, e.g., subcutaneously, intradernally, or intramuscularly. Thus, the invention provides compositions for parenteral administration which comprise a solution of the immunogenic peptides dissolved or suspended in an acceptable carrier, preferably an aqueous carrier. A variety of aqueous carriers may be used, e.g., water, buffered water, 0.4% saline, 0.3% glycine, hyaluronic acid and the like. These compositions may be sterilized by conventional, well known sterilization techniques, or may be sterile filtered. The resulting aqueous solutions may be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile solution prior to administration. The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions, such as buffering agents, tonicity adjusting agents, wetting agents and the like, for example, sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, sorbitan monolaurate, triethanolamine oleate, etc.
- For solid compositions, conventional nontoxic solid carriers may be used which include, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium carbonate, and the like. For oral administration, a pharmaceutically acceptable nontoxic composition is formed by incorporating any of the normally employed excipients, such as those carriers previously listed, and generally 10-95% of active ingredient, that is, one or more peptides of the invention, and more preferably at a concentration of 25%-75%.
- As noted above, the peptide compositions are intended to induce an immune response to the peptides. Thus, compositions and methods of administration suitable for maximizing the immune response are preferred. For instance, peptides may be introduced into a host, including humans, linked to a carrier or as a homopolymer or heteropolymer of active peptide units. Alternatively, the a “cocktail” of polypeptides can be used. A mixture of more than one polypeptide has the advantage of increased immunological reaction and, where different peptides are used to make up the polymer, the additional ability to induce antibodies to a number of epitopes. For instance, polypeptides comprising sequences from extracellular regions of α and β chains may be used in combination. Useful carriers are well known in the art, and include, e.g., KLH, thyroglobulin, albumins such as human serum albumin, tetanus toxoid, polyamino acids such as poly(lysine:glutamic acid), influenza, hepatitis B virus core protein, hepatitis B virus recombinant vaccine and the like.
- The use of more than one polypeptide is particularly useful to enhance the immune response against polypeptides of the invention. As demonstrated below, although the polypeptides may be derived from self Chemokine receptor molecules expressed in the patient, they can induce an immune response. In some instances, the immune response to the self polypeptide may not be sufficiently strong. In these instances, it may be necessary to break tolerance to the polypeptide. The compositions may comprise one or more of the foreign polypeptides that are sufficiently similar to the self polypeptides to induce an immune response against both the foreign and self polypeptides (see, Mamula et al. J. Immunol. 149:789-795 (1992). Suitable proteins include synthetic polypeptides designed for this purpose or polypeptide sequences from homologous proteins from natural sources, such as proteins encoded by a different allele at the same locus as the self polypeptide.
- The compositions also include an adjuvant. As used here, number of adjuvants are well known to one skilled in the art. Suitable adjuvants include incomplete Freund's adjuvant, alum, aluminum phosphate, aluminum hydroxide, N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine (CGP 11637, referred to as nor-MDP), N-acetylmuramyl-Lalanyl-D-isoglutaminyl-L-alanine-2-(1′-2′-dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)-ethylamine (CGP 19835A, referred to as MTP-PE), and RIBI, which contains three components extracted from bacteria, monophosphoryl lipid A, trehalose dimycolate and cell wall skeleton (NPL+TDM+CWS) in a 2% squalene/Tween 80 emulsion. The effectiveness of an adjuvant may be determined by measuring the amount of antibodies directed against the immunogenic peptide.
- A particularly useful adjuvant and immunization schedule are described in Kwak et al. New Eng. J Med. 327-1209-1215 (1992). The immunological adjuvant described there comprises 5% (wt/vol) squalene, 2.5% Pluronic L121 polymer and 0.2 % polysorbate in phosphate buffered saline.
- The concentration of immunogenic peptides of the invention in the pharmaceutical formulations can vary widely, i.e. from less than about 0.1%, usually at or at least about 2% to as much as 20% to 50% or more by weight, and will be selected primarily by fluid volumes, viscosities, etc., in accordance with the particular mode of administration selected.
- The peptides of the invention can also be expressed by attenuated viral hosts, such as vaccinia or fowlpox. This approach involves the use of vaccinia virus as a vector to express nucleotide sequences that encode the peptides of the invention. Upon introduction into a host, the recombinant vaccinia virus expresses the immunogenic peptide, and thereby elicits an immune response. Vaccinia vectors and methods useful in immunization protocols are described in, e.g., U.S. Pat. No. 4,722,848. Another vector is BCG (Bacille Calnette Guerin). BCG vectors are described in Stover et al. (Nature 351:456-460 (1991)). A wide variety of other vectors useful for therapeutic administration or immunization of the peptides of the invention, e.g.,Salmonella typhi vectors and the like, will be apparent to those skilled in the art from the description herein.
- The DNA encoding one or more of the peptides of the invention can also be administered to the patient. This approach is described, for instance, in Wolff et. al., Science 247:1465-1468 (1990) as well as U.S. Pat. Nos. 5,580,859 and 5,589,466.
- In order to enhance serum half-life, the peptides may also be encapsulated, introduced into the lumen of liposomes, prepared as a colloid, or other conventional techniques may be employed which provide an extended serum half-life of the peptides. A variety of methods are available for preparing liposomes, as described in, e.g., Szoka et al., Ann. Rev. Biophys. Bioeng. 9:467 (1980), U.S. Pat. Nos. 4,235,871, 4,501,728 and 4,837,028.
- The peptides or antibodies of the invention can also be used for diagnostic purposes. For instance, peptides can be used to screen for autoantibodies to ensure that the vaccination has been effective. Antibodies can be used to detect the presence of particular Chemokine receptor molecules associated with disease.
- The following examples are offered by way of illustration, not by way of limitation.
- This example describes a reproducible bioassay for CXCR3 activation.
- A stable line transfectant of NSO-1 cells expressing the cDNA for human CXCR3 was prepared according to standard techniques. The surface expression of hu-CXCR3 on the transfectants compared to untransfected parent NSO-1 cells was confirmed by FACS staining using mouse anti-human CXCR3 monoclonal antibody (R&D systems).
- To establish a bioassay for CXCR3 activation, the CXCR3 transfectant cells were cultured with either human IP-10, or the mouse anti-human CXCR3 antibody, and the physiological response of the cells was measured using a microphysiometer. This machine measures changes in the pH of the extracellular medium of the cell cultures which result from ligand receptor binding on the cell surface. These extracellular acidification rate measurements have previously been used as markers of antigen specific T cell activation and T cell epitope identification. The current assay is used to provide a biological read out for the identification of chemokine or chemokine receptor peptides involved in binding to IP- 10 or agonistic anti-CXCR3 antibody.
- The experiments indicated that human IP-10 and anti-CXCR3 antibody both triggered substantial acidification rate changes in the CXCR3 transfectants, as shown in FIG. 1. Importantly, the same ligands induce no change in acidification rate of untransfected NSO-1 cells (FIG. 1).
- This example describes synthesis of human CXCR3 derived peptides.
- A schematic representation of the surface portion of human CXCR3 is given in FIG. 2. The receptor has 4 surface portions, 4 intracellular portions and seven transmembrane portions. The surface portions were designated starting from N-terminus as SP-1, SP-2, SP-3 and SP-4.
- The peptides shown in Table 1 derived from these four surface portions were prepared by solid phase peptide synthesis. The names of the peptides are based on the surface portion of CXCR3 from which they were derived. For example, SP-1-1 means this peptide was derived from the first portion of the CXCR3 protein.
TABLE 1 Peptide Name Sequence SP-1-1 MVLEVSDHQVLNDAEVAALL-NH2 SP-1-2 ENFSSSYDYGENESDSCCTS-NH2 SP-1-3 PPCPQDFSLNFDRAFLPA-NH2 SP-2-1 DAAVQWVFGSGLCKV-NH2 SP-3-1 SAHHDERLNATHCQYN-NH2 SP-3-2 FPQVGRTALRVLQLVAG-NH2 SP-4-1 DILMDLGALARNCGRESRVDVAKS-NH2 - The ability of these receptor-derived peptides to bind anti-CXCR3 antibody was evaluated using a standard ELISA format. The peptides were dissolved in 0.1 M bicarbonate buffer and coated on a 96 well ELISA plate overnight. The excess peptides were removed and nonspecific binding sites in the wells were blocked by 0.1 % bovine serum albumin. Anti-CXCR3 antibody (0.5 μg/well) was added to these wells and incubated for 2 hours. Excess antibody was removed by washing with PBS. HRP conjugated goat anti-mouse antibody was used as secondary antibody for detection. Two of the seven receptor-derived peptides, namely SP-1-3 and SP-4-1, showed substantial binding to anti-CXCR3 antibody. Further support for the conclusion that anti-CXCR3 antibody bound two of the seven receptor-derived peptides was provided by FACS analysis of the same interactions. These studies revealed that the receptor-derived peptide SP-4-1 potently blocked binding of anti-CXCR3 antibody to the CXCR3 cell line transfectant. The receptor-derived peptide SP-1-3 provided partial inhibition of the binding of the antibody to CXCR3 transfectants. In contrast, an antibody nonbinding receptor-derived peptide, SP-2-1, failed to inhibit binding to CXCR3 transfectants. The data described here collectively demonstrate that anti-CXCR3 antibody can bind to two separate peptide portions of the CXCR3 extracellular domain.
- EXAMPLE 3
- This example demonstrates that peptide vaccines of the invention can be used to prevent EAE in mice.
- Protocols for animal experiments:
- SJL mice (6-8 weeks old) were obtained from Jackson Laboratories. They were kept in quarantine for two weeks. These mice get EAE when immunized with a peptide from proteolipid protein (PLP). The peptide sequence used for the immunization of these mice is PLP 139-151 and is amidated at the C terminus (HSLGWLGHPDKF-NH2). For the experiments, induction of the disease is considered
Day 0. Three weeks before the induction of the disease, the mice were vaccinated with Human CXCR3S-P4-1 peptide mixed with complete Freund's Adjuvant. - Preparation of peptide CFA emulsion for treatment
- 4mg of human CXCR3 SP-4-1 peptide was dissolved in 1 ml of phosphate buffered saline pH 7.4 (PBS). One ml of CFA obtained from VWR (Difco, Adjuvant Complete H37RA) was added to the peptide solution and the mixture was sonicated for 5 seconds using a fine tip sonicator. The emulsion was taken in 1 ml syringe (needed 2 syringes) fitted with a 25 gauge needle. Each mouse was given 100 μl of the emulsin under each flank near the hind legs by subcutaneous injection (total volume per mouse=200 μl, total peptide per mouse=200 μg).
- Preparation of CFA alone:
- One ml of PBS and 1 ml of CFA were mixed and sonicated for 5 seconds and the emulsin is drawn into a 1 ml syringe fitted with a 25 gauge needle. Each mouse was given 100 μl of this emulsion under each flank near hind legs by subcutaneous injection (total volume of CFA per mouse=200 μl).
- Induction of Disease:
- To an aqueous solution of peptide (4 mg per ml in PBS) equal volume of CFA was added and the mixture was sonicated for 5 seconds. The emulsion was drawn in a 1 ml syringe fitted with a 25 gauge needle and subcutaneously injected (200 μl total per mouse) in mice at the foot pad and back.
- Testing the antibody response to SP4-1 peptide
- The mice were bled at
week 0 andweek 5 and serum was tested by ELISA for the presence of antibodies against the human CXCR3 SP-4-1 peptide. Briefly, the SP4-1 peptide dissolved in 0.1 M sodium bicarbonate buffer was plated on a 96-well ELISA plate overnight. The nonspecific binding sites on the plate were coated with 0.1% bovine serum albumin solution in PBS. The wells were washed and serum (diluted in PBS) was added to the wells and incubated at room temperature for 1.5 hours. The wells were then washed and HRP conjugated anti-mouse immunoglobulin antibody was used to detect the presence of anti-SP4-1 antibodies). The results of this ELISA clearly indicate that the SP4-1 treated mice show an antibody response against this peptide. - Results of EAE study
- Sp4-1 was administered with CFA at 21 days and 14 days before induction of EAE as described above (FIG. 3). The results are shown in FIG. 4. There it can be seen that while most of the untreated and CFA treated mice showed clinical symptoms of EAE, 7 out of 8 mice treated with SP4-1 in CFA showed no clinical symptoms.
- The above examples are provided to illustrate the invention but not to limit its scope. Other variants of the invention will be readily apparent to one of ordinary skill in the art and are encompassed by the appended claims. All publications, patents, and patent applications cited herein are hereby incorporated by reference.
Claims (24)
1. A method of inducing an immune response against a chemokine receptor molecule in a patient, the method comprising administering to the patient an immunologically effective amount of a pharmaceutical composition comprising an adjuvant and an immunogenic chemokine receptor polypeptide from a extracellular region of a chemokine receptor molecule.
2. The method of , wherein the chemokine receptor is CXCR3.
claim 1
3. The method of , wherein the immunogenic peptide is conformationally constrained.
claim 1
4. The method of , wherein the immunogenic peptide is cyclized.
claim 1
5. The method of , wherein the immunogenic chemokine receptor peptide consists of between about 10 and about 50 residues.
claim 1
6. The method of , wherein the immunogenic chemokine receptor peptide consists of between about 15 and about 30 residues.
claim 1
7. The method of , wherein the immunogenic chemokine receptor polypeptide has an amino acid sequence selected from the group consisting of MVLEVSDHQVLNDAEVAALL, ENFSSSYDYGENESDSCCTS, PPCPQDFSLNFDRAFLPA, DAAVQWVFGSGLCKV, SAHHDERLNATHCQYN, FPQVGRTALRVLQLVAG, and DILMDLGALARNCGRESRVDVAKS.
claim 1
8. The method of , wherein the administration is parenteral.
claim 1
9. The method of , wherein the adjuvant is alum.
claim 1
10. A method of inhibiting recruitment of T cells to inflammation site in a patient, the method comprising administering to the patient an immunologically effective amount of a pharmaceutical composition comprising an adjuvant and an immunogenic chemokine receptor peptide from a extracellular region of a chemokine receptor molecule.
11. The method of , wherein the chemokine receptor is CXCR3.
claim 10
12. The method of , wherein the immunogenic peptide is conformationally constrained.
claim 10
13. The method of , wherein the immunogenic peptide is cyclized.
claim 10
14. The method of , wherein the immunogenic chemokine receptor peptide consists of between about 10 and about 50 residues.
claim 10
15. The method of , wherein the immunogenic chemokine receptor peptide consists of between about 15 and about 30 residues.
claim 10
16. The method of , wherein the immunogenic chemokine receptor polypeptide has an amino acid sequence selected from the group consisting of MVLEVSDHQVLNDAEVAALL, ENFSSSYDYGENESDSCCTS, PPCPQDFSLNFDRAFLPA, DAAVQWVFGSGLCKV, SAHHEDERLNATHCQYN, FPQVGRTALRVLQLVAG, and DILMDLGALARNCGRESRVDVAKS.
claim 10
17. The method of , wherein the inflammatory response is associated with multiple sclerosis.
claim 10
18. A pharmaceutical composition comprising an adjuvant and an isolated immunogenic chemokine receptor polypeptide from a extracellular region of a chemokine receptor molecule.
19. The composition of , wherein the chemokine receptor is CXCR3.
claim 18
20. The composition of , wherein the immunogenic peptide is conformationally constrained.
claim 18
21. The composition of , wherein the immunogenic peptide is cyclized.
claim 18
22. The composition of , wherein the immunogenic chemokine receptor peptide consists of between about 10 and about 50 residues.
claim 18
23. The composition of , wherein the immunogenic chemokine receptor peptide consists of between about 15 and about 30 residues.
claim 18
24. The composition of , wherein the immunogenic chemokine receptor polypeptide has an amino acid sequence selected from the group consisting of MVLEVSDHQVLNDAEVAALL, ENFSSSYDYGENESDSCCTS, PPCPQDFSLNFDRAFLPA, DAAVQWVFGSGLCKV, SAHHDERLNATHCQYN, FPQVGRTALRVLQLVAG, and DILMDLGALARNCGRESRVDVAKS.
claim 18
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/754,941 US20010006942A1 (en) | 1998-09-30 | 2001-01-04 | Chemokine receptor peptide vaccines for treatment and prevention of diabetes |
US09/818,705 US20020039578A1 (en) | 1998-09-30 | 2001-03-27 | Methods for treating disease with antibodies to CXCR3 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/164,186 US6171590B1 (en) | 1998-09-30 | 1998-09-30 | Chemokine receptor peptide for inducing an immune response |
US09/754,941 US20010006942A1 (en) | 1998-09-30 | 2001-01-04 | Chemokine receptor peptide vaccines for treatment and prevention of diabetes |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/164,186 Continuation US6171590B1 (en) | 1998-09-30 | 1998-09-30 | Chemokine receptor peptide for inducing an immune response |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/818,705 Continuation-In-Part US20020039578A1 (en) | 1998-09-30 | 2001-03-27 | Methods for treating disease with antibodies to CXCR3 |
Publications (1)
Publication Number | Publication Date |
---|---|
US20010006942A1 true US20010006942A1 (en) | 2001-07-05 |
Family
ID=22593363
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/164,186 Expired - Fee Related US6171590B1 (en) | 1998-09-30 | 1998-09-30 | Chemokine receptor peptide for inducing an immune response |
US09/754,941 Abandoned US20010006942A1 (en) | 1998-09-30 | 2001-01-04 | Chemokine receptor peptide vaccines for treatment and prevention of diabetes |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/164,186 Expired - Fee Related US6171590B1 (en) | 1998-09-30 | 1998-09-30 | Chemokine receptor peptide for inducing an immune response |
Country Status (10)
Country | Link |
---|---|
US (2) | US6171590B1 (en) |
EP (1) | EP1117429A4 (en) |
JP (1) | JP2002525338A (en) |
KR (1) | KR20010082217A (en) |
CN (1) | CN1328470A (en) |
AU (1) | AU6285399A (en) |
CA (1) | CA2345978A1 (en) |
IL (1) | IL142283A0 (en) |
NO (1) | NO20011537L (en) |
WO (1) | WO2000018431A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7407655B2 (en) | 1996-09-10 | 2008-08-05 | Millennium Pharmaceuticals, Inc. | Method of inhibiting leukocytes with human CXC chemokine receptor 3 antibody |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000506365A (en) * | 1996-01-11 | 2000-05-30 | ヒューマン ジノーム サイエンシーズ,インコーポレイテッド | Human G protein chemokine receptor HSATU68 |
US7888466B2 (en) * | 1996-01-11 | 2011-02-15 | Human Genome Sciences, Inc. | Human G-protein chemokine receptor HSATU68 |
WO2001072334A2 (en) * | 2000-03-27 | 2001-10-04 | Corixa Corporation | Methods for treating disease with antibodies to cxcr3 |
FR2817260A1 (en) * | 2000-11-29 | 2002-05-31 | Centre Nat Rech Scient | New Drosophila immune-induced molecule peptides useful for preventing or treating inflammatory and/or immune disorders |
US20050250175A1 (en) * | 2002-08-02 | 2005-11-10 | Takehiko Nomura | Bacterial cell wall skeleton component preparaion |
AU2005219322B2 (en) * | 2004-03-09 | 2008-09-18 | Kyoto University | Pharmaceutical Composition Comprising CXCR3 Inhibitor |
JP5041279B2 (en) * | 2004-04-22 | 2012-10-03 | 株式会社 Mbr | Formulation containing bacterial cell wall skeleton component |
AU2007226155B2 (en) * | 2006-03-16 | 2014-04-03 | Protagonists Ltd. | Combination of cytokine and cytokine receptor for altering immune system functioning |
CN100450552C (en) * | 2006-05-26 | 2009-01-14 | 中国医学科学院医学生物学研究所 | Vaccine for diabetes in type I, and constructing method |
WO2008149354A2 (en) | 2007-06-04 | 2008-12-11 | Rappaport Family Institute For Research In The Medical Sciences | Agents for the treatment of inflammatory diseases and methods of using same |
US20100227824A1 (en) * | 2008-10-10 | 2010-09-09 | Chai Ezerzer | Pharmaceutical peptides for the treatment of inflammatory diseases |
WO2010103517A1 (en) * | 2009-03-12 | 2010-09-16 | Rappaport Family Institute For Research In The Medical Sciences | Soluble compositions for the treatment of cxcr3-ligand associated diseases |
WO2014186842A1 (en) * | 2013-05-22 | 2014-11-27 | Monash University | Antibodies and uses thereof |
TW201718851A (en) * | 2015-09-18 | 2017-06-01 | 通用醫院公司 | Modified natural killer cells having ANTI-FUGETACTIC properties and uses thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6537764B1 (en) * | 1995-01-19 | 2003-03-25 | Children's Medical Center Corporation | Method of identifying inhibitors of C—C chemokine receptor 3 |
CA2242908A1 (en) | 1996-01-11 | 1997-07-17 | Human Genome Sciences, Inc. | Human g-protein chemokine receptor hsatu68 |
WO1998011218A1 (en) | 1996-09-10 | 1998-03-19 | Theodor-Kocher Institute | Cxcr3 chemokine receptor, antibodies, nucleic acids, and methods of use |
US6528625B1 (en) * | 1996-10-28 | 2003-03-04 | Millennium Pharmaceuticals, Inc. | Anti-CCR5 antibodies and kits comprising same |
SE9801098D0 (en) | 1998-03-30 | 1998-03-30 | Astra Pharma Prod | receptors |
-
1998
- 1998-09-30 US US09/164,186 patent/US6171590B1/en not_active Expired - Fee Related
-
1999
- 1999-09-30 CN CN99813897A patent/CN1328470A/en active Pending
- 1999-09-30 KR KR1020017004091A patent/KR20010082217A/en not_active Application Discontinuation
- 1999-09-30 AU AU62853/99A patent/AU6285399A/en not_active Abandoned
- 1999-09-30 EP EP99950128A patent/EP1117429A4/en not_active Withdrawn
- 1999-09-30 JP JP2000571948A patent/JP2002525338A/en not_active Withdrawn
- 1999-09-30 IL IL14228399A patent/IL142283A0/en unknown
- 1999-09-30 CA CA002345978A patent/CA2345978A1/en not_active Abandoned
- 1999-09-30 WO PCT/US1999/022992 patent/WO2000018431A1/en not_active Application Discontinuation
-
2001
- 2001-01-04 US US09/754,941 patent/US20010006942A1/en not_active Abandoned
- 2001-03-26 NO NO20011537A patent/NO20011537L/en not_active Application Discontinuation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7407655B2 (en) | 1996-09-10 | 2008-08-05 | Millennium Pharmaceuticals, Inc. | Method of inhibiting leukocytes with human CXC chemokine receptor 3 antibody |
Also Published As
Publication number | Publication date |
---|---|
IL142283A0 (en) | 2002-03-10 |
EP1117429A1 (en) | 2001-07-25 |
NO20011537D0 (en) | 2001-03-26 |
JP2002525338A (en) | 2002-08-13 |
CA2345978A1 (en) | 2000-04-06 |
KR20010082217A (en) | 2001-08-29 |
US6171590B1 (en) | 2001-01-09 |
EP1117429A4 (en) | 2002-11-20 |
CN1328470A (en) | 2001-12-26 |
NO20011537L (en) | 2001-05-28 |
WO2000018431A1 (en) | 2000-04-06 |
AU6285399A (en) | 2000-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6171590B1 (en) | Chemokine receptor peptide for inducing an immune response | |
JP4745872B2 (en) | Ligands for receptors on the surface of activated CD4 + T cells (ACT-4-L) | |
US6458360B1 (en) | Soluble complement regulatory molecules | |
PT726952E (en) | Receptor on the surface of activated t-cells:acts-4 | |
WO2000012130A1 (en) | Rp105 agonists and antagonists | |
EP0578932B1 (en) | IL-2 receptor gamma chain molecule | |
EP0482086A1 (en) | Antagonists of gm-csf derived from the carboxyl terminus | |
WO2001046260A2 (en) | Novel immunoglobulin superfamily members apex-1, apex-2 and apex-3 and uses thereof | |
AU713067B2 (en) | Cyclic peptide vaccines for treatment and prevention of diabetes | |
US7122193B1 (en) | Retro peptides, antibodies thereto and their uses for vaccination and in vitro diagnosis | |
JPH10505750A (en) | Cytotactin derivatives that stimulate adhesion and axonal growth and methods of making and using same | |
WO2001072334A2 (en) | Methods for treating disease with antibodies to cxcr3 | |
US6093693A (en) | B cell activation | |
CN1082053A (en) | Synthetic polypeptide | |
US20020039578A1 (en) | Methods for treating disease with antibodies to CXCR3 | |
EP0914453A1 (en) | HUMAN INTERLEUKIN-1j AND ANTAGONISTS THEREOF | |
JP2002508171A (en) | New ABC transporter | |
JPH11243969A (en) | New murd | |
CA2101468A1 (en) | Composition for isolating apamin receptors, apamin binding protein, and uses thereof | |
JPH10323193A (en) | New compound | |
US5591824A (en) | Porcine apamin binding protein/receptor | |
JPH11137277A (en) | New gre a | |
US20050244868A1 (en) | Ten-M3 polypeptides and polynucleotides and their methods of use | |
JPH11206389A (en) | New rpoa | |
JPH11127875A (en) | New lspa |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |